Everolimus (RAD001) activity in renal and hepatocellular carcinoma cells resistant to sunitinib and sorafenib

被引：0
|
作者：
Serova, Maria [1 ,2 ]
Riveiro, Maria Eugenia [1 ,2 ]
Dokmak, Safi [1 ,2 ]
Faivre, Sandrine [1 ,2 ]
Raymond, Eric [1 ,2 ]
机构：
[1] Beaujon Univ Hosp, RayLab, U728, Clichy, France
[2] Beaujon Univ Hosp, Dept Med Oncol, Clichy, France
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4488
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4488
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Jennifer A. Chan
    Robert J. Mayer
    Nadine Jackson
    Paige Malinowski
    Eileen Regan
    Matthew H. Kulke
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1241 - 1246
  • [22] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1241 - 1246
  • [23] Administration of RAD001 in patients with metastasized renal cell carcinoma
    Gruenwald, V.
    Gschwend, J.
    ONKOLOGE, 2009, 15 (05): : 512 - +
  • [24] Antitumor effects of everolimus, sorafenib, and axitinib in human renal cells carcinoma xenografts resistant to first line treatment by sunitinib
    Serova, Maria
    Dos Santos, Celia
    Tijeras-Raballand, Annemilai
    Riveiro, Maria-Eugenia
    de Gramont, Armand
    Faivre, Sandrine
    Raymond, Eric
    CANCER RESEARCH, 2012, 72
  • [25] Adrenocortical Cancer: A Therapeutic Approach with Everolimus (RAD001)
    Gueorguiev, M.
    Bhattacharya, S.
    Grossman, A.
    NEUROENDOCRINOLOGY, 2010, 92 (01) : 33 - 33
  • [26] Everolimus (RAD001) and solid tumours : a 2008 summary
    Levy, A.
    Sauvin, L. Albiges
    Massard, C.
    Soria, J. -C.
    BULLETIN DU CANCER, 2008, 95 (12) : 1205 - 1211
  • [27] PHASE-3 RANDOMISED TRIAL OF EVEROLIMUS (RAD001) VS PLACEBO IN METASTATIC RENAL CELL CARCINOMA
    Escudier, B.
    Ravaud, A.
    Oudard, S.
    Hutson, T. E.
    Porta, C.
    Bracarda, S.
    Gruenwald, V.
    Thompson, J.
    Figlin, R. A.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 45 - 45
  • [28] Phase I Study of Sorafenib in Combination With Everolimus (RAD001) in Patients With Advanced Neuroendocrine Tumors (NET)
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    PANCREAS, 2011, 40 (02) : 326 - 326
  • [29] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors (NET)
    Chan, J. A.
    Mayer, R. J.
    Jackson, N.
    Malinowski, P.
    Regan, E.
    Kulke, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] RAD001 (everolimus) synergizes with ZD1839 (gefitinib) in NSCLC cells resistant to EGFR-TKI
    Dong, Song
    Wu, Yi-Long
    Zhu, Jian-Quan
    An, She-Juan
    Zhang, Xu-Chao
    Guo, Ai-Lin
    CANCER RESEARCH, 2009, 69
12345